Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Joe E. who wrote (5077)	8/5/1998 3:03:00 PM
From: Joe E.	Read Replies (1) of 6136

Probably today's weakness is related to the release of Agouron's 10K, wherein management implicitly states the plan to reinvest all of their cash flow into drug development. The market does not believe right now that drug development r+d (except at major pharmas) will have high returns. Could be right or could be wrong. Major pharmas have a tax advantage in drug research, but can somebody explain any other advantage??

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next